The value-for-money of adjuvant aromatase inhibitors: time to put the debate to rest?

Aromatase inhibitors are the most effective medications today for treating or preventing the recurrence of estrogen-fueled breast cancers in post-menopausal women. Patients react differently to aromatase inhibitors, but few experience side effects severe enough to interfere with daily life. Aromatase inhibitors are among the most effective medications today for treating or preventing the recurrence of estrogen-fueled breast cancers in post-menopausal women. Unlike the potentially serious side effects of tamoxifen, including blood clots, strokes, and endometrial cancer, the AIs are easier. They can cause some cardiac issues and, the more common worry, more bone loss (osteopenia and osteoporosis). Most women who take an AI have a bone density exam every year or two to monitor their bone strength.

For this report, studies that reported pain, stiffness, and functioning outcomes as a secondary endpoint were still included. According to the study of tevaarwerk et al.20, the survival probability of advanced breast cancer patients at the 15-year was approximately 5%. We adopted a 15-year time horizon with each simulation cycle of 4 weeks in the base case analysis.

Over a 15-year time horizon, the probabilities of death for abemaciclib, palbociclib, and ribociclib were 99.0%, 95.3%, and 92.3% in our study, respectively. The WTP threshold was set at three times the GDP ($37,7378 in 2023), in accordance with the Chinese pharmacoeconomic evaluation guide21. The primary outcomes of our model included total costs, life-years (LYs), quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios (ICERs), all of which were discounted by 5% 21, aligned with the standard pharmacoeconomics modeling practices in China.

• The final invasive disease-free survival analysis displayed efficacy results at 90.7% by 36 months in ribociclib combined with NSAI while 87.6% was in the solo NSAI arm.
• The cost for Aromasin 25 mg oral tablet is around $1,211 for a supply of 30 tablets, depending on the pharmacy you visit.
• In the third stage, the full articles of potentially relevant studies were retrieved, and those that met the inclusion criteria were included in the current review.
• In 2007, the median monthly cost after deductible was about $40 for each of the three AI agents (Tables 1 and 2).

What types of hormone therapy are used for breast cancer?

Both exemestane and anastrozole are approved by the FDA for treatment of women with ER-positive breast cancer. Although both are also used for breast cancer prevention, neither is approved for that indication specifically. The role of the general internist in the care of breast cancer survivors is increasing as the number of women living with breast cancer continues to rise. Most breast cancers occurring in women older than 50 years are http://danskjagtformidling.dk/understanding-trenbolone-acetate-uses-effects-and/ estrogen receptor– and/or progesterone receptor–positive, and adjuvant endocrine therapy plays an important role in the treatment plan. Aromatase inhibitors are becoming the preferred endocrine therapy, and general internists caring for breast cancer survivors need to be familiar with their use and adverse effect profile. This article reviews the use of aromatase inhibitors, the frequency of common adverse effects, and strategies for their management.

Specifically, as the utility value of PFS decreased to 0.753, the ICER increased to $34,474 per QALY, which remained below the WTP threshold of $37,738 in China. In the case of RIB + FUL versus PAL + FUL, the cost of ribociclib emerged as the critical model factor, as depicted in Fig. 3, with other parameters showing medium or minor influences on the outcome. Furthermore, for ABE + FUL versus RIB + FUL, the discount rate had the most significant effect on the results, as shown in Fig. Regardless of how the parameters varied within the established range, the ICERs consistently exceeded the WTP threshold of $37,738.

What Are Menopausal Hot Flashes? Symptoms, Causes, Diagnosis, Treatment, and Prevention

China’s healthcare system faces pressures from rapid population aging, fragmented insurance coverage, and disparities in access to high-cost therapies. Unlike high-income countries, out-of-pocket expenses remain substantial for patients, even under national insurance schemes18. The cost-effectiveness of the three CDK4/6 inhibitor plus fulvestrant therapies in China has yet to be determined. In this study, we evaluate the cost-effectiveness of palbociclib, ribociclib, and abemaciclib plus fulvestrant in the second-line treatment of HR+/HER2 − advanced or metastatic breast cancer from the Chinese healthcare perspective. Our pharmacoeconomic assessment aims to support decision-making for policymakers, medical teams and patients, ensuring the rational allocation of medication resources and healthcare expenditure.

As the study time horizon lengthened, the extended PD phase in the RIB + FUL group gradually showed its advantages, increasing its overall QALYs gains. Nevertheless, the improved long-term survival benefits underscore why ribociclib plus fulvestrant (RIB + FUL) remains the most cost-effective option. They effectively inhibit tumor cell proliferation, and delay or overcome the development of endocrine resistance8.